Exelixis Expands its Biotherapeutics Portfolio with sorted by
relevance

Admin12.08.2021

Exelixis Expands its Biotherapeutics Portfolio with

3305
Admin01.10.2021

Exelixis Expands its Biotherapeutics Portfolio with

9901
Admin11.09.2021

Andrew Lloyd & Associates - International Technology

53010
Admin26.07.2021

Exelixis (EXEL) Stock Price, Quote & News | Stock Analysis

3207
Admin23.07.2021

InDevR Expands Commercial Portfolio for Coronavirus

6200
Admin20.07.2021

Novartis Reports Results of Five-year P-III MEASURE 1 and

5801
Admin01.09.2021

Green Cross Biotherapeutics

94010
Admin02.10.2021

Medexus expands its US product portfolio by acquiring

9608
Admin21.07.2021

HiFiBiO Therapeutics | Antibody Drug Discovery | Immune

5304
Admin10.10.2021

Exelixis inks deal with WuXi Bio - BioProcess

7607
Admin16.07.2021

JRS Pharma joins forces with Celonic

1902
Admin20.09.2021

Green Cross Biotherapeutics

4405
Admin07.09.2021

AbbVie | LinkedIn

90010
Admin03.09.2021

Adaptate Biotherapeutics raises $18 m in Series A2 funding

5503
Admin09.09.2021

Viscgo completes £315k investment round

9702
Admin05.10.2021

Innocoll Biotherapeutics initiates Phase 3 trials for

8803
Admin28.07.2021

BRIEF—Ipsen appoints new general manager in France

Admin31.08.2021

Chiesi creates Boston rare disease unit ahead of Fabry

4304
Admin23.08.2021

Sonoma Biotherapeutics catapults to $40 million in its

8900
Admin30.09.2021

Chutes & Ladders—Sanofis CMO takes on chief digital

Admin02.09.2021

GamaMabs murlentamab extends PFS in colorectal cancer

4706